Trials Sponsors Conditions Drugs Pricing

Conditions

Early Stage Endometrial Cancer Estrogen Receptor-positive

Outcome Measures

Primary Outcomes (2)

Absolute change in in ER expression by H-score
2 years
Percentage change in ER expression by H-score
2 year

Secondary Outcomes (8)

Absolute change in in PR expression by H-score
2 years
Percentage change in PR expression by H-score
2 years
Absolute change in Ki-67 by IHC scoring
2 years
Percentage change in Ki-67 by IHC scoring
2 years
Pathological response rate
2 years
+3 more secondary outcomes

Study Arms (1)

Camizestrant

EXPERIMENTAL

Camizestrant 75mg QD for 4 weeks (+/- 2 weeks) prior to surgery

Drug: Camizestrant

Interventions

CamizestrantDrug

Camizestrant is an oral selective ER antagonist and degrader

Camizestrant

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Participants must provide informed consent prior to undergoing any study-specific procedures.
Participants must have a histologically confirmed, newly diagnosed, resectable endometrial adenocarcinoma with the following characteristics determined by local pathology:

Sponsors & Collaborators

University Health Network, Toronto
Otherlead

Study Sites (6)

BC Cancer - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada

Yvette Drew, FRCPC, MBBS, PhDCONTACT

Yvette Drew, FRCPC, MBBS, PhDPRINCIPAL INVESTIGATOR

Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada

Rania Chehade, MD, FRCPCCONTACT

The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada

Johanne Weberpals, MDCONTACT

Princess Margaret Cancer Centre/University Health Network

Toronto, Ontario, M5G 2M9, Canada

Stephanie Lheureux, MD, PhD

MeSH Terms

Interventions

AZD9833

Study Officials

Stephanie Lheureux, MD, PhD
Princess Margaret Cancer Centre/University Health Network
PRINCIPAL INVESTIGATOR

Central Study Contacts

Stephanie Lheureux, MD, PhD

CONTACT

416-946-2818 stephane.lheureux@uhn.ca

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 18, 2026

First Posted

September 25, 2026

Study Start

October 26, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

October 26, 2028

Estimated

You may not qualify if:

Participants must not have received any previous systemic or local treatment for the new primary endometrial cancer currently under investigation. This includes surgery, radiotherapy, cytotoxic treatments, and endocrine therapies.
Participants must not have had any of the following interventions:
Use of sex-hormone-containing drugs within one month prior to the first dose of study treatment and concurrent use of hormonal treatments (such as for menopausal symptoms).
Medicinal products that are sensitive substrates (e.g. omeprazole) or substrates with narrow therapeutic index of CYP2C9 and/or CYP2C19 (e.g. warfarin and phenytoin) should be stopped at least 2 weeks before the first dose of camizestrant.
Strong CYP3A4/5 inducers (e.g. carbamazepine ) should be should be stopped at least 2 weeks before the first dose of camizestrant (3 weeks for St John's Wort)
Use of drugs known to prolong the QT interval and carry a known risk of torsades de pointes within the timeframe indicated in Table 5 (Appendix D) prior first dose of camizestrant.
Ivabradine or other drugs with a similar mechanism of action in sinoatrial cells.
Participants must not have any evidence of severe or uncontrolled systemic diseases that, in the investigator's opinion, would make participation in the study undesirable.
Participants must not meet any of the following cardiovascular criteria:
Electrolyte Abnormalities: Untreated serum or plasma potassium, magnesium, or calcium levels outside the normal limit range that could prolong the QT interval. These are: clinically significant electrolyte abnormalities with potential QT-prolonging effect including hypokalaemia, hyperkalaemia, hypo- and hyper-magnesaemia, hypo- and hyper-calcaemia.
ECG Abnormalities:
Mean resting QTcF interval \> 460 milliseconds at screening
Bradycardia (heart rate \< 60 bpm)
Clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG, such as second- or third-degree heart block, clinically significant sinus pause or sinoatrial block, other sinus node dysfunction, or bundle branch block. Patients with pacemakers or medically controlled atrial fibrillation are not excluded. Note: A digital triplicate ECG is mandated during screening
Any other condition that increase the risk of QTc prolongation or the risk of arrhythmic events such as symptomatic heart failure, congenital long QT syndrome, immediate family history of long QT syndrome and unexplained sudden death at \<40 years of age, hypertrophic cardiomyopathy and clinically significant stenotic valve disease.
+9 more criteria

Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (8)

Study Arms (1)

Camizestrant

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (6)

MeSH Terms

Interventions

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (8)

Study Arms (1)

Camizestrant

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (6)

MeSH Terms

Interventions

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations